Merck shares were down $3.19, or 10.2 percent, at $28.12 on the New York Stock Exchange after The Wall Street Journal reported that internal e-mails and marketing materials show the company knew as far back as 2000 that Vioxx was linked to an increased risk of heart attack but tried to discredit such evidence.
Merck shares were down $3.19, or 10.2 percent, at $28.12 on the New York Stock Exchange after The Wall Street Journal reported that internal e-mails and marketing materials show the company knew as far back as 2000 that Vioxx was linked to an increased risk of
